Relationship between adverse drug reactions of daratumumab and blood drug concentration in patients with multiple myeloma
Objective To investigate the relationship between adverse drug reactions and plasma concentration of daratu-mumab in patients with multiple myeloma.Methods A total of 78 patients with multiple myeloma admitted to our hospi-tal from July 2021 to February 2023 were selected as the study subjects.The patients received intravenous infusion of daratumab,and the blood concentration and adverse reactions of 1 week,2 weeks,4 weeks and 8 weeks after treatment were observed and recorded.Spearmen grade correlation was used to analyze the correlation between daratumab blood concentration and adverse reactions.ROC curves were used to analyze the predictive value of daratumab blood concentra-tion monitoring on adverse reactions.Results The plasma concentrations detected in 78 patients with multiple myeloma after intravenous infusion of daratumab increased with the extension of treatment time at 1 week,2 weeks,4 weeks and 8 weeks(P<0.05).With the extension of treatment time,the concentration of daratumumab in patients with multiple my-eloma adverse reactions at the end of the 1st,2nd,4th and 8th weeks increased sequentially,and the difference was statis-tically significant(P<0.05).The results of Spearmen grade correlation analysis showed that the incidence of adverse reactions increased significantly in the 1st,2nd,4th and 8th weeks,while the blood concentration of daratumab was posi-tively correlated with adverse reactions(P<0.05).ROC curve analysis showed that daratumab blood concentration mo-nitoring had a certain predictive effect on the occurrence of adverse reactions,the best cut-off value was 4.03 mg/L,and the AUC was 0.921(95%CI:0.859~0.984,P<0.05).Conclusion The adverse drug reactions of daratumum-ab in patients with multiple myeloma are significantly correlated with blood concentrations,and the blood concentration of daratumumab has predictive value for whether adverse drug reactions occur,and timely and accurate monitoring of daratu-mumab blood concentration can help guide the clinical treatment of patients with multiple myeloma.